Trevi Therapeutics, Inc. TRVI Loans Payable, Noncurrent
Loans Payable, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermLoansPayable.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 20, 2024, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s loans payable, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s loans payable, noncurrent?
- Trevi Therapeutics, Inc. (TRVI) reported loans payable, noncurrent of $2.15M in Q4 2022.
- How has Trevi Therapeutics, Inc.'s loans payable, noncurrent changed year-over-year?
- Trevi Therapeutics, Inc.'s loans payable, noncurrent decreased by 75.1% year-over-year, from $8.65M to $2.15M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s loans payable, noncurrent?
- Over 2 years (2020 to 2022), Trevi Therapeutics, Inc.'s loans payable, noncurrent has grown at a -60.7% compound annual growth rate (CAGR), from $13.95M to $2.15M.